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Abstract
Children with epilepsy often present with pervasive cognitive and behavioral comorbidities including working memory
impairments, attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder. These non-seizure
characteristics are severely detrimental to overall quality of life. Some of these children, particularly those with epilepsies
classified as Landau-Kleffner Syndrome or continuous spike and wave during sleep, have infrequent seizure activity but
frequent focal epileptiform activity. This frequent epileptiform activity is thought to be detrimental to cognitive
development; however, it is also possible that these IIS events initiate pathophysiological pathways in the developing brain
that may be independently associated with cognitive deficits. These hypotheses are difficult to address due to the previous
lack of an appropriate animal model. To this end, we have recently developed a rat model to test the role of frequent focal
epileptiform activity in the prefrontal cortex. Using microinjections of a GABAA antagonist (bicuculline methiodine)
delivered multiple times per day from postnatal day (p) 21 to p25, we showed that rat pups experiencing frequent, focal,
recurrent epileptiform activity in the form of interictal spikes during neurodevelopment have significant long-term deficits
in attention and sociability that persist into adulthood. To determine if treatment with ACTH, a drug widely used to treat
early-life seizures, altered outcome we administered ACTH once per day subcutaneously during the time of the induced
interictal spike activity. We show a modest amelioration of the attention deficit seen in animals with a history of early life
interictal spikes with ACTH, in the absence of alteration of interictal spike activity. These results suggest that
pharmacological intervention that is not targeted to the interictal spike activity is worthy of future study as it may be
beneficial for preventing or ameliorating adverse cognitive outcomes.
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It is widely believed that frequent epileptiform events seen in
children with epilepsy are capable of causing deleterious
alterations in developing brain networks and are therefore
associated with the high incidence of cognitive deficits and
psychiatric comorbidities in these patients [1,2]. It has been
suggested that when the EEG is normalized, these impairments
are often reduced or eliminated [3,4]. This line of thinking has led
to the idea that, like overt seizures, EEG interictal discharges
should also be treated [5]. However, it is unknown if the
epileptiform activity itself, some downstream consequence of the
epileptiform activity, or a combination of both of these mecha-
nisms negatively impacts cognition in the developing brain.
We have recently shown selective deficits in measures of
attention and sociability in adult animals with a history of interictal
spikes (IIS) in the prefrontal cortex (PFC) during development.
The PFC was chosen based on the preponderance of PFC-related
comorbidities in children with pediatric epilepsy. We hypothesized
that pharmacological treatment could improve the IIS activity and
that this treatment could also ameliorate these associated
behavioral deficits.
The drug H.P. Acthar gel was chosen to test these hypotheses.
The primary active compound in Acthar gel is adrenocorticotro-
phic hormone (ACTH), which is part of the hypothalamic-pituitary-
adrenal (HPA) axis and leads to downstream release of cortisol in
humans. ACTH is commonly used in epilepsies with frequent IIS
and has been shown to decrease seizure frequency and normalize
the EEG [6–9]. Treatment with ACTH in our model could
therefore lead to increased attentiveness during a behavioral task
and improvements in social behavior. Interestingly, we show that
ACTH administration modestly, but significantly, ameliorates the
attention deficit in animals with a history of IIS, but it does so
without alteration of IIS activity itself. The mechanism for this is
yet unknown, and ACTH does not seem to be effective in
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improving social behaviors in our model. Understanding when
and how ACTH is effective in improving cognition may lead to
new treatments for cognitive deficits associated with pediatric
epilepsy that are independent of the treatment of seizures.
Materials and Methods
Ethics Statement
All experiments were performed in strict accordance with the
guidelines set down by the National Institutes of Health and the
Geisel School of Medicine at Dartmouth for the humane
treatment of animals. The animal protocol was approved by the
Institutional Animal Care and Use Committee of Dartmouth
College (IACUC protocol number 09-08-01). All surgeries were
performed under isoflurane anesthesia (2–3% in oxygen) and
5 mg/kg ketoprofen was used as an analgesic post-operatively. All
efforts were made to minimize animal pain and utilize the smallest
number of animals necessary to achieve the goal of the study.
Animals
Animals were housed 2 animals per cage on a 12:12 light: dark
cycle with access to standard rat chow and water ad libitum unless
otherwise noted. Behavioral data presented herein are pooled from
three experimental cohorts of animals. The first cohort, containing
only a control (N = 5) and an untreated IIS group (N = 5) and an
additional two cohorts contain a control group (N = 4), an
untreated IIS group (N = 4) and a treated IIS group (N = 8).
Overview of Study Design
See Figure 1 for full experimental design. Animals were
chronically implanted unilaterally in the right PFC with a cannula
attached to two EEG leads. Saline or a GABAA antagonist
(bicuculline methiodine) was infused through the cannula multiple
times per day for five consecutive days during development and
local EEG was recorded at the time of infusion. Bicuculline-
injected animals developed interictal spike (IIS)-like events on the
EEG, with minimal seizure involvement. The long-term effect of
treatment with ACTH on later PFC-related cognition was
examined.
Surgery
Sprague-Dawley male rat pups (Charles River Laboratories,
Wilmington, MA) age p17, p18 or p19 (Fig. 1) were implanted
with custom-made cannula/EEG electrodes (Plastics One, Roa-
noke, VA). Each implant had a 26 G guide cannula fitted with a
33 G dummy cannula. The guide and injection cannula measured
6 mm in length, the dummy cannula was 6.2 mm in length.
Affixed to either side in the medial/lateral direction were two EEG
wires, 7 mm each in length, which were attached to a Mill-Max
connector (Mill-Max Manufacturing Corporation, Oyster Bay,
NY). The electrode/cannula set up was implanted into the right
prefrontal cortex so that the tip of the guide cannula sat at the
following coordinates; 3.0 mm anterior to bregma, 0.8 mm to the
right of midline, 2.5 mm ventral to the surface of the brain.
Implants were held in place with grip cement (DentSply
International, York, PA). All animals were treated with 5 mg/kg
ketoprofen every 4 hrs as needed during the post-surgical recovery
phase.
Early-life Epileptiform Activity Model
After a 2–4 day recovery period, animals were injected
intracortically with 0.5–0.7 mL of 200 mM bicuculline methiodine
(BMI) using a pump that delivered fluid unilaterally to the right
PFC at 0.2 mL/minute. From p21–p25, animals were injected a
total of 19 times. Three intracerebral infusions were made on the
first day, with four infusions made per day on each of the four days
thereafter. Injections were separated by approximately 1 hour.
Littermate controls were also chronically implanted with an
electrode/cannula and injected with sterile saline at the same time
as BMI in the IIS group (Fig.1). Continuous intracranial EEG was
recorded after each BMI infusion from a location adjacent to the
injection site and referenced to a common cerebellar electrode.
Figure 1. Experimental design. Animals were implanted at p17, p18 or p19 and allowed to recover for 2–5 days before the early life IIS began.
Early life IIS took place from p21–p25 with infusions of bicuculline methiodine or saline, 3–4 infusions per day spaced 1 hour apart. Three groups of
animals were used, a control infused with sterile PBS and two IIS groups infused with BMI, one treated with ACTH and one untreated. Control and
untreated IIS groups received subcutaneous vehicle injections at the same time as ACTH group received ACTH. EEG was recorded immediately post
BMI injection in both IIS groups. All behavioral experiments were conducted from p45 onward in order to evaluate the long-term effect of ACTH on
IIS-associated behavioral deficits.
doi:10.1371/journal.pone.0089812.g001
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Recordings were made for 25–30 mins in order to ensure IIS
activity was achieved. Presence of behavioral and electrographic
seizures was visually monitored in real time and video recorded.
Spike width and spike rate were calculated semi-automatically
using a MATLAB (Mathworks, Torrance, CA) function that
identified putative spike events in an EEG trace. EEG containing
putative spike events were separated from the entire trace and
visually confirmed as true events or artifact on the basis of shape
and kinetics. Width of true spike events was calculated using a
MATLAB function that measured time from peak to trough.
ACTH
IIS and littermate control animals were injected subcutaneously
with either vehicle or H.P. Acthar Gel (ACTH, obtained from
Questcor pharmaceuticals). Vehicle control gel was also obtained
from Questcor pharmaceuticals and had the same composition as
Acthar diluent. ACTH injections were made once per day, 1 hr
before BMI injections began. A dose of 150 IU/m2 (international
units per meter squared) was injected. Subcutaneous injection was
chosen to maximize duration of release of the drug. Body surface
area (BSA) was estimated as follows: surface area (in cm2) = 9.16
(mass in grams)2/3 [10]. BSA measurements per cm2 were
multiplied by a factor of.0001 to obtain BSA in m2. BSA
measurements (in m2) were then multiplied by the 150 IU/m2 to
obtain a daily dose in IU. Acthar Gel was provided in 5 mL vials
containing 80 IU of ACTH per mL. N = 8 animals were treated
with ACTH, N = 8 animals were treated with vehicle.
Delayed Non-match to Sample (DNMS)
An operant box (Med Associates Inc., St. Albans, VT) enclosed
in a dimly lit, sound-attenuating chamber was used for delayed
non-match to sample (DNMS) experiments. Inside the box, two
retractable levers were located on one wall separated by a pellet
dispenser. The opposite wall contained a nose-poke hole. Stimulus
lights were located above each lever, the food cup and the nose-
poke hole. Food pellets were used as rewards (45 mg purified
rodent dustless precision food pellet F0021; Bio-Serv, Frenchtown,
NJ). Animals were food deprived to approximately 85–90% of
predicted weight according to the growth chart provided by
Charles River Laboratories for Sprague-Dawley rats. During this
time, each animal received 14.5 g of food per day, in addition to
any food pellets rewarded during the task. DNMS sessions were
done one session per day, 7 days a week at approximately the
same time each day.
The DNMS task involved several training steps before a full trial
could be executed. Rats were initially trained to associate both
freely available levers with food reward (labeled ‘‘PR1’’). They
were then trained to press only one extended lever (‘‘Lever Press’’),
and subsequently trained to place their snout in the nose hole
when the light above it was illuminated. This last training part was
first performed while the operant box lights were switched off
entirely to encourage the rat to follow the illuminated light about
the nosepoke hole (‘‘Nosepoke Dark’’) and then in a dimly-lit
operant box (‘‘Nosepoke Light’’). Criteria for advancing through
these training sessions were as follows; bar presses: .25 rewards
received, with both levers pressed at least once each; nose-poke
dark: .25 rewards received, nose poke light: .10 rewards. If ,10
rewards were given in a session, rats were demoted to the previous
session stage.
A final training session was a forced lever-nosepoke-opposite
lever session (‘‘L-NP-L’’). The rat was presented with one lever
(sample phase), had to press the lever, break the nose-poke beam
in the opposite wall, and was then presented only the lever (test
phase) that was not presented before (non-match lever). A
successful press of the test lever in less than 10 s was associated
with a food reward, or else the trial would reset.
Once animals were able to perform this type of forced trial with
an 80% response rate (.40 trials), they advanced to ‘‘DNMS
training’’ trials, which contained the full DNMS paradigm with a
0 s delay. Here rats were presented with both test levers and had
to press the one that was not presented in the sample phase.
During this training paradigm, an error during one trial (i.e., the
rat chose the match lever instead of the non-match lever) resulted
in a subsequent forced L-NP-L as in the previous training step.
Once criterion (80% correct on the DNMS trials) was achieved
within the DNMS training session, full DNMS sessions began.
DNMS was done in blocks with increasing delay times during
the nosepoke phase; block 0 had a 0 s delay, block 1 had trials with
randomly assigned 0–5 s delays, and block 2 had trials with
randomly assigned 0–10 s delays. Criteria to pass to the next block
include accuracy of 80% or more (40 or more correct trials out of a
total of 50 trials per session) during the session and no clear lever
preference. Lever preference or less than 60% accuracy (fewer
than 30 correct trials) resulted in regression to the previous block
or phase of DNMS training. Behavioral software (Med Associates)
gave output measures on correct and incorrect trials, as well as
errors of omission: the former relating to the working memory
component of the task and the latter relating to attention during
the task. An error of omission was counted when a response was
expected from the animal and the animal failed to respond within
10 s.
Sociability
The sociability experiment was based on a previously described
mouse sociability task [11]. In brief, animals were placed in a
plexiglass box 1.22 m (480) in length and 0.41 m (160) in height
that was separated into three smaller chambers; a central chamber
measuring 0.25 m (100) in width, with adjacent right and left
chambers measuring 0.47 m (18.50) in width each that were
separated from the center chamber by a plexiglass wall with a
removable door cutout. After a 5-min acclimation phase in the
center chamber, animals were allowed to roam freely between the
left and right chamber containing a novel object and a novel age-
matched male rat, respectively for a 10-min test session. Both the
novel object and novel rat were enclosed in a mesh container with
openings large enough for only the nose of the animal in order to
ensure social approach was initiated by the test rat and not the
novel rat. The primary outcome measure in this task was the time
spent in the chamber with the novel rat vs. the time in the novel
object chamber.
Statistics
Statistics were done using Prism (GraphPad, La Jolla, CA) and
SPSS v.20 (IBM Armonk, NY). We carried out multivariable
repeated measures regression analysis using generalized estimating
equations in order to assume the correct distribution for the data.
IIS (bicuclline administration) and ACTH administration were
both modeled as predictors. The effects of litter and seizures were
also tested and were not significant in any of our experiments; the
effect of session number was modeled in our DNMS data set and
was not significant. The effect of ACTH on IIS-width and average
spike rate and all histological data was analyzed using a two-tailed
Student’s t-test, the effect of ACTH on IIS rate over time was
assessed using a repeated-measures ANOVA.
Early-Life IIS and ACTH Treatment
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Results
IIS Model
IIS activity began immediately after BMI microinjection and
lasted for 10–20 mins post-injection while the animal was awake
(Fig. 2D). Saline-injected control animals never developed IIS. All
animals were monitored in real time during the 25–30 min
recording period post-injection. IIS activity had a mean rate of
0.4560.2 spikes/s in vehicle controls, and 0.4160.08 spikes/s in
ACTH-treated animals (Fig. 2C). This rate was independent of
injection number (p = 0.41).
Brief seizures lasting less than 15 s (average length 14.960.3 s)
occurred in 8 of 17 BMI-exposed animals. There was no difference
in seizure activity between groups exposed to the ACTH and
vehicle-treated IIS animals. Overall frequency was 0.2260.10
seizures per day. Presence or absence of seizures was modeled into
all statistics and there was no significant effect of seizures in any of
our behavioral outcomes.
The Effect of ACTH on BMI-induced IIS
To determine whether or not behavioral deficits seen in animals
with a history of IIS could be ameliorated with pharmacological
treatment, animals were injected subcutaneously with ACTH one
hour before beginning BMI injection. ACTH injection did not
alter spike width, the frequency or duration of IIS as measured
during the first 20 mins post-injection EEG recording period
(Fig. 2B, C, D). Qualitatively, EEG from animals treated with
ACTH appears similar to EEG from vehicle-injected controls
(Fig. 2A).
The Effect of ACTH on IIS-induced Behaviors
A delayed non-match to sample (DNMS) task was chosen in
order to test for the presence of deficits in working memory and
attention. During the DNMS task, all animals were fed 14.5 g of
food per day; weights did not significantly differ between the
treated and untreated IIS groups during the DNMS experiment
(group mean daily weight: 238.367.1 g in control group,
228.3.965.7 g in IIS group, 214.762.5 g in IIS+ACTH group;
p.0.05). Additionally, number of rewards eaten on the first day of
the task, when rewards are freely available with the press of either
of both continuously extended levers during a fixed 20-min
session, were not different between the groups (28.662.6 pellets in
controls, 34.664.5 pellets in IIS animals, 38.865.9 pellets in IIS+
ACTH animals; p = 0.29). Taken together, all of these data
indicate that rats in all groups were equally motivated to complete
the task. We found no significant difference in number of sessions
to block completion (Fig. 3A), or in accuracy by day during any of
the blocks (accuracy in the DNMS training block show in Fig. 3B),
Figure 2. The effect of ACTH IIS activity. ACTH (A, top trace) does not have any effect on IIS activity when compared with vehicle-injected (A,
bottom trace) IIS. Both EEG traces are taken from recordings made on the second day of IIS, 10-mins after the initial BMI injection. ACTH does not
have any effect on spike width (B) or spike rate (C) or spike rate over time (D) during the 20-min post-injection EEG recording session. Bars represent
mean 6 SEM, N = 4 IIS, N = 8 IIS+ACTH.
doi:10.1371/journal.pone.0089812.g002
Early-Life IIS and ACTH Treatment
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suggesting that working memory is largely intact in IIS animals
and did not differ in IIS+ACTH animals.
However, animals with a history of IIS did make significantly
more errors of omission than control animals (1.360.4 in controls
vs. 8.361.7 in IIS). Treatment with ACTH decreased the number
of omissions errors IIS animals made during the DNMS task.
Errors of omission have previously been interpreted as a deficit in
attention during the task.
On day one of the DNMS task, one animal in the ACTH+IIS
group made 82 total omissions in one session, four times more
omissions than were ever observed in any other session from any
animal in the cohort. This session is significantly influencing the
data and is a statistical outlier (Dixon’s Q test, p,0.002, shown in
circle in inset in Fig. 3C). For this reason this single session was
eliminated from the analysis. The ACTH+IIS group averaged
4.2660.99 omissions per session, a significant decrease from the
IIS group (p = 0.03, Fig. 3C), however with the outlier session
included in the analysis the ACTH effect does not reach
significance. Despite significantly decreasing the number of
omissions made, ACTH treatment does not bring the number of
omissions back to control levels.
We next used a test of sociability to determine whether ACTH
was able to ameliorate the previously-noted IIS-induced deficits in
sociability. Unlike with the attention deficit, treatment with ACTH
did not have a significant effect on sociability in our animals (p.
0.05, Fig. 4). Both the treated and the untreated IIS groups were
not significantly sociable, spending statistically equal amounts of
time with the novel rat as the novel object. The control group was
significantly sociable, spending more time with the novel rat than
the novel object.
Data presented in the behavioral experiments represent pooled
data from three separate cohorts of animals. One of these cohorts,
containing N = 5 control and N = 5 untreated IIS animals, are in
press in a separate publication [12]. The addition of these animals
does not alter the outcome of any experiments (see Figs. S1 and
S2).
Discussion
This experimental model of early life IIS was developed to
assess the effect of focal inhibitory/excitatory imbalance resulting in
IIS activity on cognition in order to (1) control for secondary
effects of IIS on the PFC through connections from other brain
regions (2) control for global brain injury incurred during
generalized seizures. While this model may not speak directly to
pediatric epilepsies with global IIS activity or frequent generalized
seizures, our goal was to understand the long-term cognitive
consequence of frequent GABA signaling disruption and resultant
epileptiform activity on a single developing brain region whose
Figure 3. Improvements in attention after ACTH administration. Working memory as measured by cumulative number of sessions to task
completion (A) and accuracy in the training session block (B) in the DNMS task were not different after IIS, or with treatment with ACTH. However, IIS
animals (red) made significantly more omissions per session in the task than their control (blue) counterparts, and this was significantly improved
with ACTH treatment (orange) (p,0.05) (C). Inset in (C) shows the presence of an outlier (circled) in the ACTH+IIS (orange) group. The number of
omissions errors per day did not vary based on the difficulty in the working memory component of the task (D). Data points on all graphs represent
mean 6 SEM, N = 9 Control, N = 9 IIS, N = 8 IIS+ACTH.
doi:10.1371/journal.pone.0089812.g003
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dysfunction underlies cognitive deficits seen in patients with
pediatric epilepsies. We have tailored the time of exposure roughly
to the time period of development of the PFC itself. Thus in
modeling early life IIS experimentally, we hoped to understand
specific cognitive deficits seen in patients with pediatric epilepsies
such as Landau Kleffner where seizures are infrequent but
epileptiform activity is prevalent. Our subsequent goals, addressed
in this study, were to ameliorate some of these cognitive deficits
using a pharmacological agent.
To this end, we have examined the role of ACTH treatment on
IIS-associated deficits in behavior and found a modest but
significant decrease in the number of omissions made during a
DNMS task, suggesting ACTH may have a role in improving an
attention deficit associated with early life epileptiform activity.
Since ACTH is one of the few drugs that has been shown to not
only treat the symptoms of epilepsy but also normalize the EEG
[13] and is associated with better cognitive outcomes in children
with epilepsy [14], it was chosen to address the question of
whether pharmacological intervention can improve IIS-associated
cognitive deficits. The mechanism of cognitive deficits after early
life IIS is often thought to be directly related to the IIS activity
itself; however it is also possible that IIS activity initiates
deleterious downstream processes that lead to cognitive deficits.
In this study, we show that ACTH exerts its effect on the IIS-
associated attention deficit through a mechanism that does not
involve alteration of the epileptiform activity itself, suggesting IIS-
associated cognitive deficits may not be solely related to the
aberrant electrical activity. In both our model and a patient
population with epilepsy and comorbid cognitive dysfunction, it is
likely both the IIS themselves during neurodevelopment and the
underlying signaling abnormality that leads to the IIS that cause
cognitive problems. To our knowledge, this is the first time any
improvement in cognitive outcome has been shown in the context
of pediatric epilepsy in the absence of any alteration in
epileptiform activity.
ACTH has many targets in the brain and peripheral tissues.
Melanocortin receptors that bind ACTH directly are located on a
variety of different cell types throughout the CNS [15,16], and
have neuroprotective effects [17,18]. ACTH also leads to
downstream upregulation of neurosteroids that act on GABAA
receptors, can reduce neuroinflammation [19] and can also
downregulate CRH [20], which may be an endogenous
proconvulsant in developing brains [21,22]. The mechanism of
action of ACTH in epilepsy is likely a combination of these actions
working in concert and it is this wide range of anti-epileptic
properties that made it ideal for a first-pass drug for this study.
The selectivity of the ACTH effect on attention over sociability
was an unexpected but interesting result. This selectivity may be
due to a difference in the nature of the sociability versus the
DNMS task. The sociability task is a single session task, where
there is one outcome measure per animal. This makes the task less
sensitive than the DNMS attention measure, which has 5 or more
sessions per animal. ACTH does ameliorate the attention deficit,
but it does not bring it back to control levels, so it is possible that
the change in sociability may be subtle as well. The decreased
sensitivity of the sociability task suggests that subtle changes are
not measureable with this task.
The suggestion that treating the cognitive deficits may be
possible without treating the overt aberrant electrical activity has
important implications for the way epilepsies are treated in the
pediatric population [23]. Understanding the both the extent to
which ACTH can improve cognitive outcomes after early life IIS
and mechanism by which ACTH can modulate networks
underlying cognition may allow for better treatments for some of
the devastating cognitive and psychiatric comorbidities in the
future.
Conclusions
ACTH administration to animals experiencing IIS does not
change the features of the IIS. However, ACTH treatment
appears to produce some alteration in attention deficits in these
animals. This result is deserving of future study in order to
determine the extent to which ACTH can alter deleterious
cognitive outcomes, but is both surprising and exciting as it
suggests that we may be able to treat a subset of cognitive deficits
associated with abnormal EEG activity, even when we are
unsuccessful at eliminating the EEG abnormalities. Important
future directions should focus on understanding full extent to
which ACTH can alter cognitive outcomes in this and other
animal models, and subsequently understanding the mechanism
by which ACTH exerts its effects in order to identify other
potentially useful treatments for cognitive deficits in the pediatric
epilepsy.
Supporting Information
Figure S1 Improvements in attention after ACTH
administration. Working memory as measured by cumulative
number of sessions to task completion (A) and accuracy in the
training session block (B) in the DNMS task were not different
after IIS, or with treatment with ACTH. However, IIS animals
(red) made significantly more omissions per session in the task than
their control (blue) counterparts, and this was significantly
improved with ACTH treatment (orange) (p,0.05) (C). Inset in
(C) shows the presence of an outlier (circled) in the ACTH+IIS
(orange) group. The number of omissions errors per day did not
vary based on the difficulty in the working memory component of
the task (D). Data points on all graphs represent mean 6 SEM,
N = 4 Control, N = 4 IIS, N = 8 IIS+ACTH.
(TIF)
Figure S2 Deficits in sociability are not significantly
ameliorated by treatment with ACTH. Sociability as defined
Figure 4. Deficits in sociability are not significantly ameliorat-
ed by treatment with ACTH. Sociability as defined by the relative
amount of time spent with a novel rat (bars labeled ‘‘R’’) over a novel
object (bars labeled ‘‘O’’), was also altered by early life IIS. The group by
time effect can be seen as a reduction in the ratio of the amount of time
spent with the rat compared to the amount of time spent with the
object. Control animals (blue) spent a significantly greater proportion of
time with the novel rat than the novel object compared to IIS rats (red),
and the IIS rats treated with ACTH (orange). There are no significant
differences between the IIS and IIS+ACTH groups. Data points on all
graphs represent mean 6 SEM, N = 9 Control, N = 9 IIS, N = 8 IIS+ACTH.
doi:10.1371/journal.pone.0089812.g004
Early-Life IIS and ACTH Treatment
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by the relative amount of time spent with a novel rat (bars labeled
‘‘R’’) over a novel object (bars labeled ‘‘O’’), was also altered by
early life IIS. The group by time effect can be seen as a reduction
in the ratio of the amount of time spent with the rat compared to
the amount of time spent with the object. Control animals (blue)
spent a significantly greater proportion of time with the novel rat
than the novel object compared to IIS rats (red), and the IIS rats
treated with ACTH (orange). There are no significant differences
between the IIS and IIS+ACTH groups. Data points on all graphs
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